To test our hypothesis, here we evaluated the feasibility of using YC-9 (Figure 1A) for PSMA-targeted PDT to specifically enhance tumor vascular permeability and the delivery of our previously developed PSMA-targeted MNP (Figure 1B) to PSMA-expressing tumors with low vascular permeability. Here, FOLH1 is linked to neoplasm.